|
Plenary Sessions
Thursday, February 12 | Friday, February 13
Thursday, February 12
8:15-8:30 a.m.
Welcoming Remarks
8:30-10:00 a.m.
Convergence in the Sciences:
The Interaction of Nanotechnology,
Biotechnology, and Computation
The increased pace of change in many of
the sciences over the past decade has
become apparent even to the general public.
Popular magazines and the press have
highlighted the new understanding of biological
processes through such landmarks
in a science as the Human Genome Project,
the astounding changes in computational
capabilities, and the equally amazing developments
in constructing devices at the
scale of a human cell or smaller. More
recently, there has been much talk about
the possibilities emerging from a convergence
of these different disciplines, often
described as "info-nano-bio." Inevitably,
this has created a great deal of heat and
very little light. It is important to understand
what is real and what is hype in this
rapidly developing and poorly understood
interface between the sciences. The symposium
today will provide you with one window
(there are many) to the fascinating
opportunities now opening up through the
interactions of concepts and researchers
that had previously occupied separate
realms of science.
Moderator
Marvin Cassman, Executive Director,
California Institute for Quantitative
Biomedical Research
Speakers
Andrej Sali, Ph.D., Professor, Departments
of Biopharmaceutical Sciences and
Pharmaceutical Chemistry, and California
Institute for Quantitative Biomedical
Research, University of California
S. Shankar Sastry, Ph.D., Chair and
Professor, Department of Electrical
Engineering and Computer Science,
University of California
Luke Lee, Ph.D., Assistant Professor,
Department of Bioengineering,
University of California
10:00-10:30 a.m.
Coffee Break
10:30 a.m.-12 noon
Licensing in a Changing Environment
Even though the role of licensing may
change within different organizations its
importance is relatively constant. Licensing
lessons learned in the past can help guide
us as we face the uncertain future. In this
session we will learn from the past as we
visualize the role of licensing in growing
companies, from start-ups to late stage.We
will also look at a potential growing area of
interest, biogenerics. Are there licensing
issues here of which we should be aware?
Moderator
Arlene Morris, Chief Executive Officer,
Affymax
Speakers
The Role of Licensing in the Growth and
Transformation of Millennium
Vaughn Kailian, Vice Chairperson,
Millennium Pharmaceuticals, Inc.
Biogenerics: The Good, The Bad,
and The Ugly
Steve Usdin, Senior Editor,
BioCentury Publications
The Changing Biotech Model
Brian Atwood, Co-founder and Managing
Director, Versant Ventures
Friday, February 13
8:30-10:00 a.m.
Convergence: Strange Marriages,
Uncertainty and Opportunity
In science and technology, new fields, or
new connections within previously only
loosely-connected scientific fields, are
developing rapidly and providing exciting
possibilities for new technologies and great
scientific advances. For example, interfield
connections such as in silico biology (semiconductor/
biochemistry); software/biochemistry
(data mining, unclogging the masses
of sequenced data); and nanotechnologies
are emerging.
The session will focus on problems and
issues resulting from this technology convergence,
examining the impact on intellectual
property, valuation, nomenclature,
healthcare and bioethics issues, among
others. These issues have been generated by
the discontinuities in the legal, business and
ethics environment resulting from the intersection
of these new, hybrid technologies.
The lack of comfortable and well-understood
connections among science, law,
business and ethics can lead to uncertainty
and volatility - and thus to opportunity for
those who understand the issues and in
many cases to those who help define the
answers.
Moderator
Bruce W. Jenett, Co-Chair, Life Sciences
& Technology National Practice Group,
Heller Ehrman White & McAuliffe
Speakers
Leighton Read, General Partner,
Alloy Ventures
Annika M. Rienmann, Principal,
Houlihan Valuation Advisors
Paul Davis, Co-Chair, Patent & Trademark
National Practice Group, Heller Ehrman
White & McAuliffe
Kirk Hanson, Executive Director, Markkula
Center for Applied Ethics, Santa Clara
University
10:00-10:30 a.m.
Coffee Break
10:30 a.m.-12 noon
Executing Convergence with Open
Source Software: Benefit or What?
The debate on Open Source Software is
heated and diverse. What exactly is "Open
Source" and what is it not? How does a
company make money developing for open
source vs. proprietary software? How does
the strategy of a pure Open Source vendor
relate to, or differ from, that of a company
like IBM? How does Open Source provide
a freedom to operate and how does that
relate to breakthrough or converging industries
like bioinformatics? Is Open Source
an anti-IP rights business model? Does the
application of Open Source practices to
open standards address or solve the practical
RAND dilemma? Is this a class uprising
in the software business that threatens
Microsoft and other established commercial
leaders? Is it possible for companies advocating
Open Source to leverage their own
IP downstream? Where is Open Source
headed in terms of future developments
and fields beyond software?
Moderator
Don Steiny, President Institute for Social Network Analysis of
the Economy
Speakers
Mark Webbink, General Counsel,
RedHat Inc.
Jason Matusow, Shared Source Initiative
Program Manager, Microsoft
Bruce Perens, Author, Consultant and
Contributor, GNU/Linux
Richard E. Campbell, Partner, Knobbe
Martens Olson & Bear
Mike Michalyshyn, General Counsel,
QNX Software Systems Ltd.
Lawrence Rosen, General Counsel,
Open Source Initiative
|
